| answer text |
<p>Information on National Health Service expenditure on drugs for the treatment of
motor neurone disease in primary and secondary care is in the table.</p><p> </p><p><strong>
</strong></p><p> </p><p>Riluzole is the only drug defined in the British National
Formulary as being used for the treatment of motor neurone disease</p><p> </p><p>
</p><p> </p><table><tbody><tr><td colspan="3"><p>Cost of riluzole, England<sup>1</sup></p></td></tr><tr><td><p>Year</p></td><td><p>Primary
Care</p><p>(£ million)</p></td><td><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>2009</p></td><td><p>3.8</p></td><td><p>1.2</p></td></tr><tr><td><p>2010</p></td><td><p>4.9</p></td><td><p>1.4</p></td></tr><tr><td><p>2011</p></td><td><p>5.5</p></td><td><p>1.4</p></td></tr><tr><td><p>2012</p></td><td><p>5.8</p></td><td><p>1.5</p></td></tr><tr><td><p>2013<sup>2</sup></p></td><td><p>2.3</p></td><td><p>1.0</p></td></tr></tbody></table><p>
</p><p><sup>1</sup> Cost of drugs at NHS list price. It does not take account of discounts,
dispensing costs, fees or prescription charges income.</p><p> </p><p><sup>2 </sup>The
patent for riluzole expired in the first quarter of 2013.</p><p> </p><p><em>Source:
</em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social
Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index
(HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since
a drug could be prescribed to treat more than one condition and as the condition for
which a drug is prescribed is not collected, it is not possible to separate the different
conditions for which it may have been prescribed. The information provided may therefore
include costs from the prescribing of the drug for conditions other than for motor
neurone disease.</p><p> </p>
|
|
